This is a very lose base that I'll judge how much ACL seeks to raise for the Onc IPO.
Two years company running costs ~16 million
Two Ph2 trials (pro rata costs as phase 3 with ~80 ppl) ~10 million
Remainder of Phase 3 costs ~20 million
Listing fees/costs ~1 million
its all looking positive, page-26
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable